No description available.

<b>Background:</b> The aim of this thesis was to develop an evidence-based approach to the post-marketing withdrawal of medicinal products when harms are attributed to their use. <b>Methods:</b> Electronic and non-electronic searches were conducted to identify medicinal products withdrawn from the market because of adverse reactions. Data relating to the time periods between launch, first adverse reaction reports and withdrawals, the mechanism through which the adverse reactions occurred, and the countries of withdrawal were extracted. Standard criteria were used to document the levels of evidence used by drug regulators to make the withdrawal decisions; scatter plots and two-by-two tables used to explore the trends over time. A previously published algorithm was used to examine the justification for withdrawals. To examine the benefits and harms of medicinal products before regulatory approval, searches were conducted on drug regulatory websites and scientific databases. The Cochrane criterion was used to examine the risk of bias, Review Manager Software for meta-analysis, and GRADE criterion to rate the quality of evidence. <b>Results:</b> Improvements in pharmacovigilance over the past six decades have resulted in quicker detection of harms caused by approved medicinal products; however, there have not been corresponding improvements in how quickly harmful products are withdrawn from the market following the reports of harms. Harmful drugs are significantly less likely to be withdrawn in low resource settings. The quality of evidence in drug trials for which regulatory approval decisions are based is on the whole, poor. There is a lack of consistency in the methods used by drug regulators to assess the harms of medicinal products before granting marketing licences. <b>Conclusions:</b> Universally accepted guidelines for deciding when to withdraw approved medicinal products from the market should be developed. Pharmacovigilance systems in low-resource settings should be strengthened. The methods used to assess harms in clinical trials require improvement.

Thesis (Ph. D.)--Virginia Commonwealth University, 2007. / Prepared for: Dept. of Psychology. Bibliography: leaves 188-213. Also available online via the Internet.

Thesis (Ph. D.)--West Virginia University, 2009. / Title from document title page. Document formatted into pages; contains vi, 95 p. Includes abstract. Includes bibliographical references (p. 56-64).

When periodic electroconvulsive shocks (ECSs) were administered, a progressive intensification of the motor seizure (MS) pattern occurred. This effect was observed when ECSs at either 15 or 75 mA were administered at 3-day, but not 1-hr intervals. The magnitude of the increase in severity of the MS pattern was a function of the number of ECSs which approached asymptote, in these experiments, at approximately ten ECSs. Periodic ECSs were also found to potentiate the alcohol withdrawal syndrome. In general, those conditions which were found to facilitate the kindling of MSs were the same as those which produced the potentiation of the alcohol withdrawal syndrome. Furthermore, this potentiation was found to persist up to 3 weeks after the last ECS under the conditions used in these experiments. Finally, the potentiation of the alcohol withdrawal syndrome occurred even after the MSs had been pharmacologically blocked. The results of these experiments were discussed in light of their implications to both basic and clinical research. / Arts, Faculty of / Psychology, Department of / Graduate

Thesis (Ph.D.)--University of Adelaide, Dept. of Clinical and Experimental Pharmacology, 1998? / Bibliography: leaves 1-26.

Thesis (Ph.D.)--George Mason University, 2009. / Vita: p. 118. Thesis director: Robert F. Smith. Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Psychology. Title from PDF t.p. (viewed June 10, 2009\). Includes bibliographical references (p. 101-117). Also issued in print.

Thesis (M.S.)--University of Wyoming, 2008. / Title from PDF title page (viewed on June 23, 2009). Includes bibliographical references (p. 58-60).

Dissertation submitted in partial compliance with the requirements for the Master’s Degree in Technology: Homoeopathy, Durban University of Technology, 2011. / ‘Cigarette smoking is a modern day epidemic that poses a substantial health burden’, it has been proven that smokers die on average fourteen years earlier than non smokers as a direct result of their smoking. An abundance of evidence indicates that the health risks associated with cigarette smoking can however be reversed with a sufficient period of abstinence. Thus achieving life-long abstinence must be a health priority for both developing and developed countries (Caponnetto &, Polosa, 2008). Over 80% of smokers express a desire to stop smoking and 35% of them try to stop each year. However, less than 5% are successful in un-aided attempts to quit (American Psychiatric Association, 1995). The greatest challenge facing smokers who wish to quit are nicotine withdrawal symptoms; these include dysphoric or depressed mood, insomnia, irritability, frustration, anger, anxiety, difficulty concentrating, restlessness, decreased heart rate and increased appetite or weight gain (American Psychiatric Association, 1995). The aim of this double blind placebo controlled quantitative study was to determine the effectiveness of a homoeopathic complex (Caladium seguinum 30 CH, Nux vomica 30 CH and Staphysagria delphinium 30 CH); a tautopathic preparation and the combined effect thereof, in the treatment of nicotine withdrawal syndrome as determined by the Tolerance Dependence Questionnaire, Smoking History and Perceptions of Treatment Questionnaire. Methodology Forty participants recruited by means of convenience sampling were randomly and equally divided into one of four treatment groups, namely tautopathic group, homoeopathic group, combined tautopathic and homoeopathic group and placebo group. The duration of the study was 2 weeks and two consultations with each participant were conducted. The respective interventions were administered in oral spray format; participants were asked to spray their respective preparations directly into their mouth three times daily and to repeat the dose whenever they had a craving for a cigarette. iv Measurements in the form of the Tolerance Dependence Questionnaire (Appendix D), Perceptions of Treatment Questionnaire (Appendix H), and Smoking History (Appendix G) were used to quantify response to treatment. Non-parametric statistical analysis was conducted to analyse the data. Results All four research groups experienced a statistically significant reduction in the amount of cigarettes smoked, favourable perceptions of their response to treatment and improved tolerance. Statistically however when the groups were compared with each other they were similar with respect to their tolerance to nicotine, perception of response to treatment and reduction in amount smoked. Although interventions were statistically similar in terms of effectiveness, the data does suggest that Tautopathy as an intervention warrants exploration. The Tautopathic group achieved the highest reduction in the number of cigarettes smoked when comparing medians (11 less smoked per day), achieved the highest percentage of participants who experienced reduced cravings, and the highest percentage of participants who would continue using the intervention (90% respectively) as well as improvements in 6/9 variables of the Tolerance Dependence Questionnaire. Conclusions The study concludes that each of the four subject groups (including placebo) proved to be successful in aiding the participant to cease smoking. The results showed a significantly positive perception of the participants to the interventions used. The influence of the placebo effect however was very evident in this study; in addition other factors such as the unique method of administration of the medication (oral spray format on demand) the Hawthorn effect and the participants’ desire/commitment to quit smoking may have contributed to the positive results obtained. Notwithstanding the above and although not statistically significant; positive trends within the data do suggest that the Tautopathic approach used in this study should be further investigated in future.

Objectives The purpose of this study was to describe 30 people’s testimonies of their journeys from drug addiction to drug withdrawal in Taiwan. World Drug Report estimates the number of opioid users at 53 million, up 56 % from previous estimates, and that opioids are responsible for two thirds of the 585,000 people who died as a result of drug use in 2017. Methods This was a qualitative research design. The sample inclusion criteria: 1. Participants had drug abused experiences. 2. Participants received Christian Gospel Drug Withdraw Program. 3. Participants did their testimonies in the Good TV True Blog. There were 30 participants’ testimonies related to their drug withdrawn by gospel interventions during 2012-2020. These stories were posted on the Good TV channel in Chinese language in Taiwan that were written down by the author and translated from Chinese to English. The main themes were generated in this study. Results There were 24 male (80%) and 6 Female (20%) in this study. The mean age was 50.93 (SD = 10.47) (Range = 26-65). The major themes were (1) Using illegal drugs: Lack of knowledge and temptations (2) Drug addiction: An endless pain circle (3) Turning points: Love and Hope (4) Drug withdraw: Overcome the Temptations and Holy Spirit (5) Outcome: Faith and New Life. These 30 participants drug withdrew successfully, became Christians and started their new lives as well as helped other people quit drug and any other addiction. Discussion These are powerful testimonies to support that the gospel drug withdrawal programs and church activities are effective to help people drug withdrawal. These programs can be used in the Mental Health Nursing professions. Early education related to the negative impact of illegal drugs in the school is very important to prevent people’s drug addiction.